Table 1 Patient baseline characteristics
NRTa (n = 39) | Varenicline (n = 35) | NMb (n = 6) | Total (n = 80) | |
|---|---|---|---|---|
Sex | ||||
Female | 11 (28.2%) | 11 (31.4%) | 2 (33.3%) | 24 (30%) |
Male | 28 (71.8%) | 24 (68.6%) | 4 (66.7%) | 56 (70%) |
Age (years) | 62.9 (± 8.4) | 62.6 (± 7.8) | 59.5 (± 4.9) | 62.6 (± 7.9) |
BMI (kg/m2) | 25.9 (± 4.8) | 25.2 (± 4.8) | 24.8 (± 5.3) | 25.5 (± 4.8) |
Score of Fagerstroem Test | 4.7 (± 2.2) (13 missing) | 4.9 (± 2.4) (2 missing) | 4.0 (± 1.4) (4 missing) | 4.8 (± 2.3) (19 missing) |
PackYears | 41.92 (± 18) | 49.58 (± 27.51) | 36.9 (± 9.6) | 44.9 (± 22.5) |
At least one attempt for smoking cessation | 18 (46.2%) | 18 (51.4%) | 1 (16.7%) | 37 (46.3%) |
Current smoking at study entry | 26 (66.7%) | 31 (88.6%) | 1 (16.7%) | 58 (72.5%) |
Quit smoking within 4 weeks before study entry | 13 (33.3%) | 4 (11.4%) | 5 (83.3%) | 22 (27.5%) |
ECOG** | ||||
0 | 7 | 7 | 2 | 16 |
1 | 25 | 25 | 2 | 52 |
2 | 1 | 0 | 0 | 1 |
Lung-Cancer Stage | ||||
NSCLC I–II | 7 (18%) | 6 (17.1%) | 1 (16.7%) | 14 (17.5%) |
NSCLC III–IV | 17 (43.6%) | 20 (57.1%) | 2 (33.3%) | 39 (49%) |
SCLC | 15 (38.5%) | 9 (25.7%) | 3 (50%) | 27 (34%) |
Lung-Cancer Therapy | ||||
Surgery | 10 (25.6%) | 5 (14.3%) | 1 (16.7%) | 16 (20%) |
Chemotherapy or radiochemotherapy | 29 (74.4%) | 29 (82.9%) | 5 (83.3%) | 63 (78.8%) |
Radiotherapy | 0 | 1 (2.9%) | 0 | 1 (1.2%) |